Mallinckrodt PLC will soon begin operating as two independent publicly traded companies – an innovative specialty drug marketer, and a generic and active pharmaceutical ingredient developer. That's after the company announced plans to spin out its specialty generics and API business Dec. 6, pending final board approval. The spin-out is expected to be completed in the second half of 2019.
The decision is part of a strategy to position some of the business into a new pure-play specialty pharmaceutical company,...
